{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:08:31Z","timestamp":1784005711168,"version":"3.55.0"},"reference-count":9,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Gonadotropin-releasing hormone analogues (GnRHas) are an effective treatment to address the compromise in height potential seen in patients with central precocious puberty. There is no evidence in the literature of a single GnRHa used for longer than 2 years before being removed or replaced. We describe a patient who was on continuous gonadotropin suppression for 7 years and despite this, achieved a height potential within 1 SD of mid-parental height. A boy aged 10 years 3 months presented to the endocrine clinic with signs of precocious puberty and advanced bone age. Initial laboratory values were a random luteinizing hormone (LH) level of 9.4 mIU\/mL, follicle-stimulating hormone (FSH) 16.3 mIU\/mL, dehydroepiandrosterone sulfate 127 mcg\/dL, and testosterone 628 ng\/dL. The patient was initially started on Lupron injections before transitioning to a histrelin implant. Follow-up laboratory results 5 months post-suppression showed pre-pubertal random LH 0.2 mIU\/mL, FSH 0.1 mIU\/mL, and testosterone 5 ng\/dL. The patient was lost to follow-up and returned 5 years later presenting with gynecomastia and delayed bone age. He had continuous gonadotropin suppression with random LH 0.10 mIU\/mL, FSH 0.16 mIU\/mL, and testosterone 8 ng\/dL. The histrelin implant was removed, and 4 months later, his random pubertal hormone levels were LH 5.6 mIU\/mL, FSH 4.3 mIU\/mL, and testosterone 506 ng\/dL. The patient\u2019s mid-parental height was 175.3 cm and his near final height was 170.6 cm, which is within 1 SD of his genetic potential. Further studies are needed to explore continuous gonadotropin hormone suppression with a single histrelin implant beyond 2 years.<\/jats:p>","DOI":"10.1210\/jendso\/bvab189","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T19:34:28Z","timestamp":1641929668000},"source":"Crossref","is-referenced-by-count":8,"title":["Gonadotropin Suppression for 7 Years After a Single Histrelin Implant for Precocious Puberty"],"prefix":"10.1210","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1029-8694","authenticated-orcid":false,"given":"Douglas","family":"Villalta","sequence":"first","affiliation":[{"name":"The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1691-2293","authenticated-orcid":false,"given":"Jose B","family":"Quintos","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Rhode Island Hospital\/Hasbro Children\u2019s Hospital-The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"issue":"4","key":"2022011401450728700_CIT0001","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40272-015-0130-8","article-title":"Central precocious puberty: update on diagnosis and treatment","volume":"17","author":"Chen","year":"2015","journal-title":"Paediatr Drugs"},{"issue":"6","key":"2022011401450728700_CIT0002","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1210\/jc.2014-3031","article-title":"Long-term continuous suppression with once-yearly histrelin subcutaneous implants for the treatment of central precocious puberty: a final report of a phase 3 multicenter trial","volume":"100","author":"Silverman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2022011401450728700_CIT0003","article-title":"Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty","volume":"812517","author":"Rahhal","year":"2009","journal-title":"Int J Pediatr Endocrinol"},{"issue":"6","key":"2022011401450728700_CIT0004","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1542\/peds.2005-0538","article-title":"The histrelin implant: a novel treatment for central precocious puberty","volume":"116","author":"Hirsch","year":"2005","journal-title":"Pediatrics"},{"issue":"4","key":"2022011401450728700_CIT0005","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jpeds.2013.05.033","article-title":"A single histrelin implant is effective for 2 years for treatment of central precocious puberty","volume":"163","author":"Lewis","year":"2013","journal-title":"J Pediatr"},{"issue":"4","key":"2022011401450728700_CIT0006","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jpeds.2013.12.009","article-title":"Resumption of puberty in girls and boys following removal of the histrelin implant","volume":"164","author":"Fisher","year":"2014","journal-title":"J Pediatr"},{"issue":"6","key":"2022011401450728700_CIT0007","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1530\/EJE-16-1054","article-title":"Diagnostic and therapeutic approach of tall stature","volume":"176","author":"Albuquerque","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2022011401450728700_CIT0008","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1056\/NEJMcp070677","article-title":"Clinical practice. Gynecomastia","volume":"357","author":"Braunstein","year":"2007","journal-title":"New Engl J Med"},{"issue":"6","key":"2022011401450728700_CIT0009","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/andr.12636","article-title":"EAA clinical practice guidelines-gynecomastia evaluation and management","volume":"7","author":"Kanakis","year":"2019","journal-title":"Andrology"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvab189\/42099755\/bvab189.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/6\/2\/bvab189\/42184573\/bvab189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/6\/2\/bvab189\/42184573\/bvab189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T02:00:40Z","timestamp":1642125640000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvab189\/6500027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvab189","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2022,1,7]]},"article-number":"bvab189"}}